Publications by authors named "Jennifer Wheler"

100Publications

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.

J Hematol Oncol 2019 12 30;12(1):145. Epub 2019 Dec 30.

Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-019-0835-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937824PMC
December 2019

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Authors:
Sneha Berry Nicolas Giraldo Peter Nguyen Benjamin Green Haiying Xu Aleksandra Ogurtsova Abha Soni Farah Succaria Daphne Wang Charles Roberts Julie Stein Elizabeth Engle Drew Pardoll Robert Anders Tricia Cottrell Janis M Taube Ben Tran Mark Voskoboynik James Kuo Yung-Lue Bang Hyun-Cheo Chung Myung-Ju Ahn Sang-We Kim Ayesh Perera Daniel Freeman Ikbel Achour Raffaella Faggioni Feng Xiao Charles Ferte Charlotte Lemech Funda Meric-Bernstam Theresa Werner Stephen Hodi Wells Messersmith Nancy Lewis Craig Talluto Mirek Dostalek Aiyang Tao Sarah McWhirter Damian Trujillo Jason Luke Chunxiao Xu BoMarelli Jin Qi Guozhong Qin Huakui Yu Molly Jenkins Kin-Ming Lo Joern-Peter Halle Yan Lan Matthew Taylor Nicholas Vogelzang Allen Cohn Daniel Stepan Robert Shumaker Corina Dutcus Matthew Guo Emmett Schmidt Drew Rasco Marcia Brose Nicholas Vogelzang Christopher Di Simone Sharad Jain Donald Richards Carlos Encarnacion Drew Rasco Robert Shumaker Corina Dutcus Daniel Stepan Matthew Guo Emmett Schmidt Matthew Taylor Nicholas Vogelzang Carlos Encarnacion Allen Cohn Christopher Di Simone Drew Rasco Donald Richards Matthew Taylor Corina Dutcus Daniel Stepan Robert Shumaker Matthew Guo Emmett Schmidt James Mier Jeongshin An Yeun-Yeoul Yang Won-Hee Lee Jinho Yang Jong-Kyu Kim Hyun Goo Kim Se Hyun Paek Jun Woo Lee Joohyun Woo Jong Bin Kim Hyungju Kwon Woosung Lim Nam Sun Paik Yoon-Keun Kim Byung-In Moon Filip Janku David Tan Juan Martin-Liberal Shunji Takahashi Ravit Geva Ayca Gucalp Xueying Chen Kulandayan Subramanian Jennifer Mataraza Jennifer Wheler Philippe Bedard

J Immunother Cancer 2019 Feb 13;7(1):46. Epub 2019 Feb 13.

Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0519-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373015PMC
February 2019

Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study.

JCO Precis Oncol 2018 2;2. Epub 2018 Nov 2.

, , and , Analysis Group, Boston; , , and , Foundation Medicine, Cambridge, MA; and and , The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.18.00074DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446484PMC
November 2018

Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.

Mol Cancer Ther 2018 03 13;17(3):671-676. Epub 2017 Dec 13.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0673DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935561PMC
March 2018

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.

Eur J Cancer 2017 09 26;83:229-236. Epub 2017 Jul 26.

Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.06.018DOI Listing
September 2017

Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.

Int J Cancer 2017 Jan 17;140(1):208-215. Epub 2016 Oct 17.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.30417DOI Listing
January 2017

Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials.

Cancer Chemother Pharmacol 2016 07 10;78(1):167-71. Epub 2016 Jun 10.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 455, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3073-zDOI Listing
July 2016

Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.

Cancer Chemother Pharmacol 2016 05 16;77(5):1097-102. Epub 2016 Apr 16.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3000-3DOI Listing
May 2016

Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.

Cancer Chemother Pharmacol 2016 Mar 29;77(3):575-81. Epub 2016 Jan 29.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2952-zDOI Listing
March 2016

Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors.

Invest New Drugs 2015 Oct 14;33(5):1086-92. Epub 2015 Aug 14.

Memorial Sloan-Kettering Cancer Center, 300 East 66th Street, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0273-zDOI Listing
October 2015

Challenges and perspective of drug repurposing strategies in early phase clinical trials.

Oncoscience 2015 30;2(6):576-80. Epub 2015 Jun 30.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506360PMC
http://dx.doi.org/10.18632/oncoscience.173DOI Listing
August 2015

Multiple gene aberrations and breast cancer: lessons from super-responders.

BMC Cancer 2015 May 29;15:442. Epub 2015 May 29.

Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California at San Diego Moores Cancer Center, La Jolla, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1439-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446801PMC
May 2015

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.

Invest New Drugs 2015 Aug 21;33(4):911-20. Epub 2015 May 21.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-015-0251-5
Publisher Site
http://dx.doi.org/10.1007/s10637-015-0251-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492845PMC
August 2015

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.

BMC Cancer 2015 Feb 18;15:61. Epub 2015 Feb 18.

Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1029-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340232PMC
February 2015

Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.

Invest New Drugs 2015 Jun 31;33(3):621-31. Epub 2015 Mar 31.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, MD Anderson Cancer Center, Unit 455, P.O. Box 301402, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10637-015-0226
Web Search
http://link.springer.com/10.1007/s10637-015-0226-6
Publisher Site
http://dx.doi.org/10.1007/s10637-015-0226-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482235PMC
June 2015

Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.

Support Care Cancer 2015 Sep 15;23(9):2649-54. Epub 2015 Feb 15.

Department of Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 455, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs00520-015-26
Web Search
http://link.springer.com/10.1007/s00520-015-2625-9
Publisher Site
http://dx.doi.org/10.1007/s00520-015-2625-9DOI Listing
September 2015

Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.

Cancer Chemother Pharmacol 2015 Apr 10;75(4):869-74. Epub 2015 Feb 10.

Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2695-xDOI Listing
April 2015

Androgen receptors beyond prostate cancer: an old marker as a new target.

Oncotarget 2015 Jan;6(2):592-603

Center for Personalized Cancer Therapy, Division and Hematology and Oncology, Moores Cancer Center, The University of California San Diego, 3855 Health Sciences Drive, La Jolla, California.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359241PMC
http://dx.doi.org/10.18632/oncotarget.2831DOI Listing
January 2015

Unique molecular landscapes in cancer: implications for individualized, curated drug combinations.

Cancer Res 2014 Dec 17;74(24):7181-4. Epub 2014 Oct 17.

Division of Hematology and Oncology, Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-2329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292868PMC
December 2014

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.

Invest New Drugs 2015 Feb 18;33(1):177-86. Epub 2014 Oct 18.

Sarah Cannon Research Institute at HealthONE, Presbyterian/St. Luke's Medical Center, 1800 Williams Street, Suite 300, Denver, CO, 80218, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0173-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297242PMC
February 2015

MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.

Clin Genitourin Cancer 2015 Feb 3;13(1):e19-26. Epub 2014 Jul 3.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.06.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144738PMC
February 2015

Characteristics and survival of patients with advanced cancer and p53 mutations.

Oncotarget 2014 Jun;5(11):3871-9

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116527PMC
http://dx.doi.org/10.18632/oncotarget.2004DOI Listing
June 2014

Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program.

Anticancer Res 2014 May;34(5):2349-55

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, U.S.A.

View Article

Download full-text PDF

Source
May 2014

Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer.

J Natl Compr Canc Netw 2014 Feb;12(2):194-203

From the aDepartment of Investigational Cancer Therapeutics, and bDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0020DOI Listing
February 2014

Retreatment after secondary resistance or mixed response: a pilot study.

Oncology 2013 6;85(6):350-5. Epub 2013 Dec 6.

The University of Texas, MD Anderson Cancer Center, Houston, Tex.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000355691DOI Listing
March 2014

Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.

Invest New Drugs 2014 Jun 5;32(3):465-72. Epub 2013 Dec 5.

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-013-0051-8
Publisher Site
http://dx.doi.org/10.1007/s10637-013-0051-8DOI Listing
June 2014

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.

Mol Cancer Ther 2013 Dec 3;12(12):2857-63. Epub 2013 Oct 3.

Corresponding Author: Filip Janku, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, FC8.2018, Box 0455, Houston, Texas 77030.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0319-TDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158732PMC
December 2013

Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.

Clin Cancer Res 2013 Oct;19(19):5474-84

Authors' Affiliations: Departments of Breast Medical Oncology and Systems Biology, Surgical Oncology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Sarcoma Oncology Center, Santa Monica; Division of Hematology-Oncology, University of California, San Diego, California; and Celgene, Summit, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-3110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935482PMC
October 2013

Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.

Invest New Drugs 2013 Dec 28;31(6):1505-13. Epub 2013 Aug 28.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-0013-1DOI Listing
December 2013

Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.

Mol Cancer Ther 2013 Oct 20;12(10):2167-75. Epub 2013 Aug 20.

Corresponding Author: Jennifer Wheler, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Unit 455, 1400 Holcombe Boulevard, Houston, TX 77030.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-1208DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138057PMC
October 2013

Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.

Invest New Drugs 2013 Oct 2;31(5):1192-200. Epub 2013 Aug 2.

Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-0003-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809091PMC
October 2013

A pilot study of temsirolimus and body composition.

J Cachexia Sarcopenia Muscle 2013 Dec 27;4(4):259-65. Epub 2013 Jul 27.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13539-013-0113-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830004PMC
December 2013

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.

Invest New Drugs 2014 Apr 12;32(2):279-86. Epub 2013 Jun 12.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-9966-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730367PMC
April 2014

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors.

Invest New Drugs 2014 Feb 23;32(1):154-9. Epub 2013 Apr 23.

Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-9964-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913855PMC
February 2014

Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy.

J Cancer Res Clin Oncol 2013 Jun 2;139(6):963-70. Epub 2013 Mar 2.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00432-013-1404-6
Publisher Site
http://dx.doi.org/10.1007/s00432-013-1404-6DOI Listing
June 2013

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.

Target Oncol 2013 Sep 12;8(3):183-188. Epub 2013 Feb 12.

Moores Cancer Center, The University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-013-0266-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766504PMC
September 2013

A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases.

Cancer Chemother Pharmacol 2013 Apr 3;71(4):955-63. Epub 2013 Feb 3.

Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2088-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977741PMC
April 2013

PIK3CA mutations in advanced cancers: characteristics and outcomes.

Oncotarget 2012 Dec;3(12):1566-75

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681495PMC
http://dx.doi.org/10.18632/oncotarget.716DOI Listing
December 2012

A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

Invest New Drugs 2013 Aug 20;31(4):918-26. Epub 2012 Nov 20.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-012-9898-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482128PMC
August 2013

Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver.

Cancer Chemother Pharmacol 2013 Feb 11;71(2):389-97. Epub 2012 Nov 11.

Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-012-2014-8DOI Listing
February 2013

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Cancer Res 2013 Jan 12;73(1):276-84. Epub 2012 Oct 12.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-1726DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537862PMC
January 2013

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

Clin Cancer Res 2012 Nov 10;18(22):6373-83. Epub 2012 Sep 10.

Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-1627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454458PMC
November 2012

Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience.

J Clin Oncol 2012 Aug 9;30(23):2891-6. Epub 2012 Jul 9.

Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2011.38.0758
Publisher Site
http://dx.doi.org/10.1200/JCO.2011.38.0758DOI Listing
August 2012

Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.

Cancer 2012 Dec 6;118(24):6144-51. Epub 2012 Jun 6.

Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27647DOI Listing
December 2012